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https://doi.org/10.1016/j.celrep.2020.108153SUMMARYInnate lymphoid cells (ILCs) are important for response to infection and for immune development in early life.
HIV infection in adults depletes circulating ILCs, but the impact on children infected from birth remains un-
known. We study vertically HIV-infected children from birth to adulthood and find severe and persistent
depletion of all circulating ILCs that, unlike CD4+ T cells, are not restored by long-term antiretroviral therapy
unless initiated at birth. Remaining ILCs upregulate genes associated with cellular activation and metabolic
perturbation. Unlike HIV-infected adults, ILCs are also profoundly depleted in tonsils of vertically infected
children. Transcriptional profiling of remaining ILCs reveals ongoing cell-type-specific activity despite anti-
retroviral therapy. Collectively, these data suggest an important and ongoing role for ILCs in lymphoid tissue
of HIV-infected children from birth, where persistent depletion and sustained transcriptional activity are likely
to have long-term immune consequences that merit further investigation.INTRODUCTION
In the absence of antiretroviral therapy (ART), HIV disease pro-
gression is typically more rapid in infected children compared
to adults, with more than 50% mortality in HIV-infected children
by 2 years of age (Goulder et al., 2016; Marston et al., 2011;
Muenchhoff et al., 2014; Newell et al., 2004; Roider et al.,
2016). In adult HIV infection, disease control is associated both
with high CD4+ T cell levels and low viral loads, as well as with
strong HIV-specific adaptive immune responses (Goulder and
Walker, 2012; Koup et al., 1994).Cel
This is an open access article undIn pediatric HIV infection, however, only limited adaptive im-
munity operates to control viremia (E. Adland, 2014, IAS, confer-
ence; Adland et al., 2015; Muenchhoff et al., 2014). A subgroup
of infected children (10%) maintain long-term HIV control that is
associated with low immune activation of their T cells despite
high viral loads (Muenchhoff et al., 2016; Roider et al., 2016).
These individuals, termed ‘‘pediatric slow progressors’’ (PSPs),
share several immunological features with the sooty mangabey
natural hosts of simian immunodeficiency virus (SIV) infection,
including modulation of type I interferon (IFN) pathways (Mandl
et al., 2008; Meier et al., 2009) rather than strong HIV-specificl Reports 32, 108153, September 15, 2020 ª 2020 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Silvestri, 2016). In addition, non-pathogenic SIV of African green
monkeys is associated with the migration of natural killer (NK)
cells into lymphoid follicles through membrane-bound IL-15 on
dendritic cells (Huot et al., 2017). This suggests innate lymphoid
cell (ILC) subsets are involved in the prevention of disease in tis-
sue, and these cells may play an important role in AIDS resis-
tance in PSPs as well as in the natural hosts of SIV infection.
ILCs are a heterogenous group of lymphoid cells that do not
express rearranged antigen receptors and therefore do not
respond directly to antigen presentation (Vivier et al., 2018).
They are grouped into helper and cytotoxic ILCs (NK cells) with
functions and transcription factor expression overlapping that
of CD4+ T-helper cells and cytotoxic CD8+ T cells, respectively.
In the blood of HIV-infected children, NK cell expansion and acti-
vation occurs during the first year of life (Slyker et al., 2012) but
declines with age irrespective of ART-mediated viral suppres-
sion (Azzoni et al., 2005); these NK cells appear to become
dysfunctional (Ballan et al., 2007). Indeed, uninfected children
of HIV-infected mothers display higher NK cell killing activities
in the first 6 months of life compared to HIV-unexposed children
(Smith et al., 2017). These studies suggest that NK cells in blood
respond to HIV exposure and infection from birth. However, the
impact of lifelong HIV infection on NK cells in lymphoid tissue,
where they exert their effector function, remains unknown.
Helper ILCs are sentinels of infection at tissue sites where they
are involved in maintaining homeostasis and repair after injury or
infection (Shah et al., 2017). For example, we recently showed
that ILCs are enriched in the human lung during active tubercu-
losis infection and are important for the early recruitment of mac-
rophages (Ardain et al., 2019). Non-human primate studies of SIV
infection show that ILCs display elevated apoptosis and cyto-
toxic phenotypes and are depleted in the gut (Klatt et al., 2012;
Reeves et al., 2011), oral mucosae (Li and Reeves, 2013), and
lymph nodes (Xu et al., 2015). In acute adult HIV infection, we
observed irreversible ILC depletion from the blood unless treat-
ment was initiated during early acute stages (Kløverpris et al.,
2016). Subsequently, the loss of ILCs was shown to be directly
linked to HIV-induced inflammatory cytokines (Wang et al.,
2020). ILCs can respond to HIV infection at mucosal tissue sites
(Fernandes et al., 2018; Kim et al., 2012) through type I IFN path-
ways (Wang et al., 2020) and FAS-FASL-induced apoptosis
(Zhang et al., 2015) and are associated with markers of gut bar-
rier breakdown and reduced IL-7 levels (Kra¨mer et al., 2017),
suggesting that ILCs are involved in tissue homeostasis during
adult HIV infection (Shah et al., 2017). Interestingly, however,
we found no depletion of ILCs from the tonsils or lungs of HIV-in-
fected adults (Ardain et al., 2019; Kløverpris et al., 2016), sug-
gesting that depletion of resident ILCs across tissues is not uni-
versal in adult HIV infection.
ILC composition is determined during early life in direct
response to intestinal commensal microbial colonization (Gury-
BenAri et al., 2016; Sonnenberg et al., 2012) and is regulated
by the maternal microbiota (Gomez de Ag€uero et al., 2016) and
maternal HIV exposure (Bender et al., 2016). Therefore, we hy-
pothesized that lifelong HIV infection might have a different
impact on circulating and tissue-resident ILCs than in adults.
We studied a total of 229 newborns (NBs), children, and adults2 Cell Reports 32, 108153, September 15, 2020and mapped the circulating and tissue-resident ILC and NK
cell response to HIV infection from birth; we observed striking
ILC depletion in both the blood and tonsil tissue of infected chil-
dren. Moreover, we found distinct cell-type-specific transcrip-
tional changes in activation and metabolism, suggesting a
potentially important role for innate lymphocytes in response to
HIV infection in early life.
RESULTS
Helper ILCs in Blood Display a Distinct Transcriptional
Profile Compared to NK Cells and Are Enriched in
Children Compared to Adults
To evaluate the role of ILCs in pediatric HIV infection, we first es-
tablished a gating strategy to analyze ILCs and NK cells in blood
based on distinct phenotype expression (Lim et al., 2017; Spits
et al., 2013). We excluded lineage+ cells and used ILC- and
NK-specific markers to simultaneously identify three different
ILC (ILC1, ILC2, ILC pre-cursers [ILCPs]) (Lim et al., 2017) and
two different NK cell populations (NK CD56high and NK CD16high)
(Figure 1A). We performed RNA sequencing (RNA-seq) of sorted
ILC2, ILCP, NK CD56high, and NK CD16high populations from 10
pediatric participants (median age 10.8 years, interquartile range
[IQR] 6.4–11.9 years; Table S1). Principal component analysis
(PCA) using 497 differentially expressed genes (DEGs) (false dis-
covery rate [FDR]-corrected q < 0.01; see Method Details)
demonstrated clean separation of these ILC subsets (Figure 1B;
Table S2). Genes separating the subsets include granzyme B
(GZMB), IFN-g (IFNG), CD16 (FCGR3A), and KIR2DL1 ex-
pressed in NK populations; and high levels of KLRB1 (CD161),
KLRG1, CCR4, IL9R, and IL1RL1 (ST2), which binds IL-33 for
activation in ILC2s (Figure 1C; Table S2). Thus, our flow cytom-
etry panel successfully identifies the main ILC and NK cell sub-
sets in pediatric blood, which also display the canonical gene
signatures observed in adults.
Because the relative frequencies of many blood immune sub-
sets change across the course of the normal lifespan (Prender-
gast et al., 2012; Shearer et al., 2003), we first studied ILC and
NK levels in HIV-uninfected individuals spanning birth, child-
hood, and adulthood, in each case using samples from sub-Sa-
haran African cohorts in Durban, South Africa (Table 1). Overall,
among 138 HIV-uninfected individuals with an age range of 0–24
years, we found a strong reduction in the frequency of all ILC
subsets with age (Figure 1D), whereas NK cell populations re-
mained relatively stable (Figure 1E), consistent with a recent
study (Ve´ly et al., 2016). Together, these data define the circu-
lating ILC populations present in children from sub-Saharan Af-
rica and establish their normal frequencies in the absence of
HIV infection.
Depletion of All Circulating ILC Subsets in Treatment-
Naive HIV-Infected Children Irrespective of Disease
Control
Mortality among vertically HIV-infected children exceeds 50%
by the age of 2 years in the absence of ART (Marston et al.,
2011; Newell et al., 2004). Here, we studied a group of 26 un-
treated vertically transmitted children that survived to the age
of minimum 5 years in two different groups: (1) PSPs (median
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Figure 1. Circulating ILC Populations Decrease during the Course of Immune Maturation
(A) Gating strategy including lineage markers (CD3, CD4, CD11c, CD14, CD19, CD34, CD303, TCRgd, TCRab) to identify two dominant NK populations defined
by CD56high(green) and CD16high (purple) and three ILC subsets: ILC1 (orange), ILC2 (red), and ILCP (light blue).
(B) Principal component analysis (PCA) and heatmap shown for each replicate for each participant (see Table S1).
(C) DEGs among ILC2, ILCP, CD56high (NKCD56), and CD16high (NKCD16) NK cell populations from four HIV-negative and six HIV-positive pediatric subjects.
(D) Frequencies of total helper ILC subsets as defined in (A), comparing HIV-negative newborn (NB) (n = 39), pediatric (2–5 years, n = 12), pediatric (>5 years, n =
25), and adult (n = 62) individuals expressed as percentage of total CD45+ lymphocytes.
(E) As in (C) but showing frequencies of total NK and subset-specific differences between pediatric and adult subjects.
p values by Dunn’s multiple comparisons test.
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OPEN ACCESSCD4= 37%, IQR 28%–44%, n = 15) and (2) pediatric progressors
(PPs) (median CD4 = 15%, IQR 8%–28%, n = 11) whometWorld
Health Organization (WHO) criteria prevailing at the time of the
study to initiate antiretroviral treatment (Table 1; Figure 2A). Total
ILC frequencies and all individual helper ILC subsets (ILC1, ILC2,
and ILCPs) were significantly decreased compared to uninfected
controls. However, there were no significant differences be-
tween PSPs and PPs (Figure 2B). Overall, the NK populations
showed a similar pattern of depletion, though mostly found
within the CD56high NK subset (p < 0.0002) (Figure 2C). Thus,
all helper ILCs and NK cells are severely depleted in children in-
fected with HIV at birth, even among the rare group of PSPs, whomaintain normal-for-age CD4 levels (Figure 2A) despite being
ART naive.
ILC Depletion in the Blood Is Sustained Despite Viral
Suppression by ART but Can be Prevented by Immediate
ART Treatment Initiation at Birth
We have previously reported that long-term ART in chronic adult
infection is unable to restore circulating ILC levels (Kløverpris
et al., 2016). However, HIV-infected children appear to possess
a superior ability to restore adaptive immune function compared
to adults (Lewis et al., 2012; Picat et al., 2013). Therefore, we
next investigated the impact of long-term ART in pediatric HIVCell Reports 32, 108153, September 15, 2020 3
Table 1. Clinical Characteristics of 229 Newborn, Pediatric, and Adult Subjects
Cohort HIV Transmission n Agea ART Weeks on ART CD4% Viral Load (VL)b
Newborns HIV none 39 23 (20–30) (h) NA NA 51 (43–54) NA
Infants HIV none 12 48 (36–57) (min) NA NA 32 (7–43) NA
Infants HIV+ in utero 27 21 (12–24) (min) yes 79 (51–103) 30 (26–35) <20
Pediatric HIV none 25 8.8 (7.0–12.0) (years) NA NA 37 (28–44) NA
Pediatric HIV+ PSP vertical 15 12.6 (11.0–14.1) (years) no NA 30 (22–37) 9,500 (1,450–53,000)
Pediatric HIV+ PP vertical 11 7.6 (6.8–12.7) (years) no NA 15 (8–28) 110,000 (21,000–510,000)
Pediatric HIV+ PART vertical 38 11.9 (8.6–15.2) (years) yes 88 (40–218) 30 (19–36 <20
Adult HIV uninfected none 62 21 (20–22) (years) NA NA 41 (37–45) NA
HIV, HIV uninfected; HIV+, HIV infected; ART, antiretroviral therapy; NA, not applicable
aMedian
bHIV RNA copies/ml plasma
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88 weeks (IQR 40–218) (Table 1). As in adult HIV infection, ART
failed to restore total ILCs, ILC1, ILC2, ILCPs, and NK cells (Fig-
ure 3A). Longitudinal sampling of the PP cohort (n = 9) over three
time points from a median of 12 weeks before treatment and
again at 42 and 84 weeks after treatment initiation showed the
same trend. Although a modest increase in both NK CD56high
cells and ILCPs was observed, neither of which reached levels
of uninfected controls (Figure 3B). This lack of ILC or NK cell
reconstitution was confirmed in additional longitudinal cohorts
undergoing viral suppression by ART or maintaining high CD4
levels in the absence of treatment over 84 weeks (Figure S1).
Our previous work demonstrated that early treatment of HIV-
infected adults, prior to peak viremia, prevents significant loss
of circulating ILCs (Kløverpris et al., 2016). To test this, we next
examined the effect of early treatment initiation on circulating
ILC subsets in a cohort of 27 in-utero-infected newborns
(NBs), initiated on ART within minutes after birth (Adland et al.,
2020). ART was initially prophylactic (nevirapine and zidovudine)
and then increased to triple therapy treatment from a median of
7 days post-partum (range 0–18 days), with all individuals re-
maining undetectable for plasma HIV RNA at 21 months of age
(Table 1). Strikingly, in these individuals, we found no difference
in CD4+ T cell, ILC, or NK cell levels compared to age-matched
HIV-uninfected children (Figure 3C). Thus, immediate ART initia-
tion of in-utero-infected NBs preserves ILC and NK cell levels,
which is consistent with that seen in adult horizontal HIV infection
(Kløverpris et al., 2016).
Peripheral ILCs and NK Cells Are Transcriptionally
Activated in the Blood of HIV-Infected Children
To investigate whether blood ILCs in children are modulated by
HIV infection, we measured surface ex vivo activation marker
expression CD69 and FAS (CD95) and cytokine production (IL-
2, IL-4, IL-5, IL-13) following mitogen stimulation on ILC2,
ILCP, NKCD56high, andNKCD16high subsets. HIV had no impact
on expression of CD69 and Fas on ILC2s and ILCPs, while NK
CD56high and NK CD16high subsets displayed increased expres-
sion of Fas and CD69 (Munneke et al., 2014) (Figure S2A), indi-
cating that they are stimulated by HIV infection. In the mitogen
stimulation assay of ILC2s, we found no impact of HIV infection
on cytokine production (Figure S2B).4 Cell Reports 32, 108153, September 15, 2020To further explore the impact of HIV on ILCs in circulation in in-
fected children, we performed RNA-seq on ILC2, ILCP, NK
CD56high, and NK CD16high subsets and CD4+ T cells from three
ART-naive viremic PSPs, three ART-treated virally suppressed
children, and four age-matched HIV-uninfected children (see Ta-
ble S1 for replicate numbers and Method Details). Differential
gene expression analyses on each subset between HIV-infected
children (PSP+ ART+/–) and HIV-uninfected controls demon-
strated >300 DEGs (FDR-corrected q < 0.1) in each of the
CD4+ T cells, ILC2s, ILCPs, and NK CD16high cells and 61
DEGs in NK CD56high cells (Figure 4A; Table S3). Comparisons
between both virally suppressed and viremic HIV-infected chil-
dren and between virally suppressed HIV-infected children and
HIV-uninfected controls revealed few transcriptional changes
in all cell subsets (<57 and <49, respectively), suggesting that
persistent viremia drives transcriptional changes in circulating
ILCs (Figure 4B; Table S3).
Analysis of the DEGs observed in all subsets is consistent with
the activation and loss of regulatory function of ILC subsets in
chronically HIV-infected children. We note the following DEGs
in each subset comparing HIV-infected children to healthy con-
trols (Figure 4C; Table S3): (1) ILC2s: downregulation of inflam-
matory markers PTGS2, NFKBID, and TNF and upregulation of
anti-apoptosis marker BIRC3, H4 clustered histone 3
(HIST1H4C), and SUB1, a transcription factor that mediates
RNA polymerase binding; (2) ILCPs: downregulation of ILC3 line-
age transcription factor RORC (Serafini et al., 2015) and upregu-
lation of pro-survival markers (AXL, MET) and cytokine-induced
transcription factor STAT4; (3) NK CD16high: downregulation of
the mTORC-activating factor KLHL22 (Chen et al., 2018) and up-
regulation of TNFRSF9 (CD137), an activation marker of NK cells
(Baessler et al., 2010) known to promote T cell expansion (Wilcox
et al., 2002), and GK encoding glycerol kinase, an essential
enzyme for glycerol conversion; and (4) NK CD56high: downregu-
lation of canonical transcription factors involved in negative
regulation of cellular proliferation and differentiation (DUSP6,
FOS) and upregulation ofMORC3, which recruits p53 and other
transcription machinery (Sloan et al., 2016; Takahashi et al.,
2007), and IFI30, an IFN-stimulated response gene. Moreover,
genes involved in active metabolism like COX7A2, NDUFB6
(ILC2), NDUFA12 (ILCP), ACSL1 (NK CD16high), and DNAJA4
(NK CD56high) were upregulated in HIV-infected children,
AB
C
Figure 2. Depletion of Peripheral Helper ILC and Cytotoxic NK Cell Subsets in Treatment-Naive HIV-Infected Pediatric Subjects
(A) CD4 percentage of CD45+ lymphocytes (left) and plasma viral load (right) of pediatric HIV-uninfected (HIV) subjects (n = 25), pediatric slow progressors (PSPs)
(n = 15), and pediatric progressors (PPs) (n = 11) (see Table 1).
(B) As in (A) but showing total ILC (left), ILC1 (center left), ILC2 (center right), and ILCP (right) subset levels as percentage of CD45+ lymphocytes. Gating as in
Figure 1A.
(C) As in (B) but showing total NK cells (left) and NK subsets (CD56high, middle; CD16high, right) as percentage of CD45+ lymphocytes.
p values by Dunn’s multiple comparisons test.
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infection.
Gene set analysis using ingenuity pathway analysis (IPA)
highlighted oncogenes ESR1, RET, and MYC as significantly
enriched and upregulated upstream drivers potentially
inducing the transcriptional changes in all ILC subsets (except
for ESR1 in ILC2s and MYC in NK CD16high cells) between
HIV-infected children and healthy controls (Figure 4D; Table
S4). Consistent with a role for IFN in chronic HIV infection
(Roff et al., 2014), IFN-g is also significantly enriched, though
lacking in ILC2s. These upstream drivers are corroborated by
enrichment for genes associated with protein ubiquitination in
all ILC subsets in downstream pathway analysis (Figure 4E;
Table S4). Surprisingly, both ILC2s and ILCPs exhibit signifi-
cant enrichment for pathways annotated for defects in cellular
metabolism—mitochondrial dysfunction and unfolded protein
response, respectively. To confirm these metabolic gene sig-
natures, we performed gene set enrichment analysis (GSEA)
on the DEGs from each ILC subset using the Gene Ontology
(GO) and KEGG databases (see Method Details). In both
ILC2s and ILCPs, several GO and KEGG terms encompassingcellular activation and metabolism were positively enriched
(Figure 2C; Table S4). GSEA on NK CD16high DEGs implicated
pathogen recognition receptor signaling and response to
stress, while no terms were significant for enrichment from
NK CD56high DEGs (Method Details). Together, these data
demonstrate that peripheral ILC2s, ILCPs, NK CD16high, and
NK CD56high subsets all express activation gene programming
in HIV-infected children compared to HIV-uninfected controls.
Moreover, enrichment results suggest differences in cellular
metabolism in ILC2s and ILCPs.
Reduced ILC and NK Levels in Tonsils from HIV-Infected
Children
While the role and function of helper ILCs in the blood are un-
known, ILCs play a key role in human lymphoid tissue devel-
opment (Koues et al., 2016; Ve´ly et al., 2016) and in response
to inflammation (Bernink et al., 2013). Using tonsils from chil-
dren undergoing tonsillectomy as a source of secondary
lymphoid tissue (Table S5) (Roider et al., 2019), we identified
six different innate lymphocyte populations from lineage-
negative cells (Figure S3A), which were dominated by NK cellsCell Reports 32, 108153, September 15, 2020 5
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Figure 3. Sustained Depletion of All Peripheral ILC and NK Subsets in Virally Suppressed Children in the Absence of Treatment Initiation at
Birth
(A) Cross-sectional comparisons of all blood helper ILC and NK subsets in pediatric HIV-uninfected and virally suppressed (VL <20 HIV RNA copies/ml plasma)
pediatric subjects treated for a median of 88 weeks (IQR 40–218) with median CD4% of 37 (IQR 26–35) and 30 (IQR 19–36), respectively.
(B) Longitudinal sampling of pediatric subjects (n = 9) before treatment initiation and at two time points after treatment intervention: time point 1 = 12 weeks before
starting ART, time point 2 = 42 weeks after treatment, and time point 3 = 84 weeks after treatment when patients have fully suppressed plasma viral loads and
reconstituted CD4 percentages (see also Figure S1). The dotted lines represent normal levels of HIV-negative pediatric subjects.
(C) Blood CD4, helper ILC, and NK subset percentages in HIV-uninfected infants aged 2–5 years (infant HIV; n = 12; petrol) and HIV+ and viral-suppressed (VL
<20 HIV RNA copies/ml plasma) infants aged 0.2–3 years (infant HIV+; n = 27; orange).
p values by Dunn’s multiple comparisons test.
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expression of CD103 and CD69, described as surrogate
markers for tissue residency (Masopust and Soerens, 2019;
Skon et al., 2013) (Figure 5A). Overall, CD127– NK cells and
NKp44+ ILC3s expressed higher levels of these markers of tis-
sue residence compared to ILC1, ILC2, and CD127+ NK cells,
consistent with mouse model experiments (Gasteiger et al.,
2015) (Figure 5B). To test if tonsil-resident ILCs also were
reduced by HIV infection, we compared the relative frequency
of each of the tonsil NK and ILC subsets from 12 HIV-negative
children to that of 4 ART-treated HIV-positive children in
whom the ART initiation was unknown, of which 3 were virally
suppressed (viral load <20 copies/ml plasma) with detectable
antiretroviral drugs in plasma (Table S5). We found highly sig-
nificant depletion for each ILC and NK subset (Figure 5C) but,
surprisingly, no significant depletion of bulk CD4+ T cells or
PD-1++CD69+ T-follicular helper-like cells in the same sub-
jects (Figure S3D), in contrast to our previous work in adult
tonsils where we found no HIV-associated ILC depletion (Klø-
verpris et al., 2016). Although the number of HIV-infected chil-
dren studied here is small, these data suggest that HIV infec-
tion from birth has a more severe impact on tissue-resident
ILCs than does infection in later life.6 Cell Reports 32, 108153, September 15, 2020Transcriptional Profiling of NK and ILC3 Cells in Tonsils
from HIV-Infected Children Reveals Subset-Specific
Activation in Response to Infection
Next, to study the ILC and NK cell responses to HIV infection in
pediatric tissue, we purified the dominant ILC (ILC3 NKp44–,
ILC3 NKp44+) and NK cell subsets (NK CD127–) from pediatric
tonsils, while insufficient cell numbers were available from ILC1
and ILC2 subsets (see Figure S3A), and performed transcrip-
tional profiling directly ex vivo to characterize both the transcrip-
tional differences between the subsets and their responses to
HIV infection (Figure 6). In HIV-uninfected controls, a limited
number of genes separated the two ILC3 subsets defined by
NKp44 surface expression (238 DEGs, FDR-corrected q < 0.1)
compared to >1,000 genes for both ILC3 subsets compared to
NK CD127– cells (Figure 6A; Table S6). In the top 20 regulated
genes between ILC3 subsets were NCR2, which encodes
NKp44, and S1PR1 (CD69), which is associated with tissue res-
idency (Skon et al., 2013); both are consistent with protein sur-
face expression on ILC3 subsets (see Figure 5 and
Figure S3A). Comparison of the NK CD127– and ILC3 subsets
showed strong differential expression of canonical genes known
to be upregulated in ILC3s (ICAM1, ICOS, IL1R1,RORC, IL17RE,
KIT, ICOS, CD83) whereas NK CD127– cells expressed genes
A B
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Figure 4. Blood ILC Subsets Are Transcriptionally Activated during
Chronic Pediatric HIV
(A and B) Number of DEGs in whole transcriptomes of CD4+ T cells, ILC2s,
ILCPs, CD56high, and CD16high NK cells between HIV-infected and HIV-unin-
fected pediatric subjects (A) and among HIV-uninfected, HIV-infected treated
and HIV-infected untreated pediatric subjects (B) (see Table S1 for subject
numbers). DEGswere called using DESeq2with a significance cut-off of FDR <
0.1.
(C) Volcano plots of the DEGs between HIV-infected (positive) and HIV-unin-
fected (negative) pediatric subjects in (A). Genes of interest are annotated with
black dots; see Table S3 for all DEGs. Dotted line annotates the significance
cut-off of FDR q < 0.1.
(D and E) Select upstream drivers (D) and canonical pathways (E) significant in
ingenuity pathway analysis (IPA) of DEGs from each ILC subset. For direc-
tionally annotated pathways, a Z-score is calculated to represent up- or
downregulation of the driver or pathway. If a driver or pathway is not direc-
tionally annotated in IPA, or there are not enough genes in the list to calculate a
Z-score, N/A is reported. See Table S4 for the full IPA results. See also Fig-
ure S2.
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OPEN ACCESSinvolved in cytotoxicity (GZMA, GZMB, CCL5, GNLY, PRF1,
IFNG) together with expression of canonical NK cell surfacemol-
ecules (FCGR3A, KLRF1, KLRG1). In addition, we found ILC3-
specific upregulation of genes associated with homing to
lymphoid follicular zones (CXCR5,CXCR4,CCR6) and regulation
of adaptive immunity (ICOS, CD40L, IFNGR2). These data are
consistent with previous analysis in human tonsils (Bjo¨rklund
et al., 2016; Cella et al., 2019; Koues et al., 2016) and suggest
that ILC3 and NK subsets have distinct functions in human
lymphoid tissue as regulators of tissue homeostasis and killing
potential, respectively.
To determine the response of each of these subsets to HIV
infection in children, we compared the transcriptional response
in ILC3 NKp44–, ILC3 NKp44+, and NK CD127– cells in tonsils
from two virally suppressed ART-treated HIV-infected children
with five age- and gender- (female) matched HIV-uninfected chil-
dren (see Table S6). We found 195, 286, and 75 DEGs (FDR-cor-
rected q < 0.1) for ILC3 NKp44–, ILC3 NKp44+, and NK CD127–
cells, respectively (Figure 6B; Table S7). We note the following
DEGs in each subset comparing HIV-infected children to healthy
controls (Figure 6C; Table S7): (1) ILC3 NKp44–: upregulation of
NF-kB co-activator PRMT6 (Di Lorenzo et al., 2014), cell-cycle
antigen PCNA, and CD38, which is associated with activation
in T cells, but previously undescribed on ILCs; (2) ILC3
NKp44+: downregulation of NF-kB inhibitor MAST2 (Xiong
et al., 2004) and upregulation of cell-cycle-associated TUBB2A,
anti-inflammatory ANXA1 (Arcone et al., 1993), and lineage
commitment protein ID1, whose family member ID2 is known
to regulate ILC differentiation in tissue (Zhong and Zhu, 2017);
and (3) NK CD127–: upregulation of secreted pattern recognition
receptor lectin CLEC18A shown to be associated with hepatitis
C infection and Notch signaling pathway genes JAG2 and
NOD2. Notch signaling has been shown to upregulate killer
immunoglobulin-like receptor (KIR) expression and drive matu-
ration in NK cells (Felices et al., 2014), suggesting that this NK
CD127– subset may play an extended effector role in the tonsil
in HIV infection.
To examine the CD4+ T cell response to HIV infection in pedi-
atric tonsils, we sorted four different CD4+ T cell populations
based on CD103/PD-1 expression (Figure S4A) accounting forCell Reports 32, 108153, September 15, 2020 7
AB
C
Figure 5. Lymphoid Tissue-Resident ILCs Are Reduced in the Tonsils of HIV-Infected Children
(A) Gating of CD69 and CD103 co-expression from each of the six innate subsets as indicated above flow plots (see Figure S3).
(B) Frequencies of CD69 (left), CD103 (center), and combined CD69/CD103 (right) expression on six innate tonsil NK/ILC cell populations as defined in (A) in 15
pediatric subjects. p values by Dunn’s multiple comparisons test.
(C) Frequencies of each of the six innate lymphocyte population in tonsils, comparing pediatric HIV-uninfected (HIV; n = 12) and HIV-infected (HIV+; n = 4)
subjects. (See also Figure S3). P values by Mann-Whitney U test.
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of innate lymphocytes (Table S7). The PD-1++CD103 subset ex-
pressed high levels of the canonical T follicular helper (Tfh) cell
genes CXCR5 and PDCD1 and low levels of ITGAE (CD103), re-
flecting the sorted phenotypes by flow (Figure S4B). Using sam-
ples collected from a separate set of children given limited sam-
ple availability (see Table S5), we compared gene expression in
each CD4+ T cell subset between HIV-infected (n = 3) and HIV-
uninfected (n = 5) children (see Method Details for design). We
found limited numbers of DEGs in all four CD4 T cell subsets (Fig-
ure S4C; Table S7), suggesting limited response from CD4+
T cells compared to that seen for ILCs and NK cells.
Gene set analysis distinguished the responses to HIV infection
by subset, with unique potential upstream drivers and pathways
significantly enriched in each (Figures 6D and 6E; Table S7).
While the ILC3 NKp44– subset expressed DEGs associated
with innate and cytokine-mediated immune signaling potentially
induced by broad transcriptional activator SP1 and epigenetic
regulator HDAC3, the enrichment on the DEGs in the ILC3
NKp44+ subset reflected general cellular activation and prolifer-
ation with potential activation by G-coupled protein receptors
and nuclear transcription factor HFN4A. Enrichment on the NK8 Cell Reports 32, 108153, September 15, 2020CD127– subset demonstrated a consistent role for NK cells in
the tonsil as innate immune sentinels during HIV infection, with
putative upstream driver PTPRM, known to regulate cellular
adhesion. GSEA using the KEGG and GO gene sets found signif-
icant enrichment only in the ILC3 NKp44– subset, supporting
broad cellular activation and proliferation with significant GO
terms encompassing protein complex assembly, signal trans-
duction by p53, and biogenesis (Figure S4D; Table S8).
In summary, the ILC and NK cells responses to pediatric HIV
infection were cell-subset specific with distinct activation and
proliferation programming. CD4+ T cells in the tonsil, on the other
hand, did not demonstrate strong transcriptional differences be-
tween HIV-infected and HIV-uninfected children. While the ILC3
NKp44+ subset did not exhibit immune activation by flow cytom-
etry, both the ILC3 NKp44– and NK CD127– subsets upregulated
machinery associated with immune response and innate im-
mune signaling. Together with the profound depletion of ILCs
and NK cells observed in vertically infected children, these
data suggest that HIV infection from birth has a persistent impact
on innate lymphocytes within secondary lymphoid organs that
may have important consequences for their downstream im-
mune health.
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Figure 6. Coordinated Transcriptional ILC3
and NK Cell Response in the Pediatric HIV-
Infected Tonsil
(A) Heatmap showing DEGs among ILC3 NKp44–,
ILC3 NKp44+, and NK CD127– subsets from four
HIV-negative pediatric tonsils performed in dupli-
cate or triplicates with canonical genes annotated.
(B) Number of DEGs in whole transcriptomes of
tonsils of ILC3 NKp44–, ILC3 NKp44+, and NK
CD127– cells among viral-suppressed (<20 HIV
RNA copies/ml plasma), HIV-infected (HIV+; n = 3),
and gender- and age-matched HIV-uninfected
pediatric subjects (HIV–; n = 4).
(C) Volcano plot showing significance plotted
against log2 fold change for DEGs in the ILC3
NKp44–, ILC3 NKp44+, and NK CD127– pop-
ulations with genes upregulated in HIV-infected
tonsils shown as positive log2 fold change (right)
and genes downregulated by HIV infection shown
as negative log2 fold change (left). Genes of inter-
est are annotated with black points and with
dotted line annotating the significance cut-off of
FDR q < 0.1.
(D and E) Upstream molecules predicted to be
involved in initiating pathways shown in (E) deter-
mined by ingenuity pathway analysis of DEGs from
the each of the three innate tonsil lymphocyte
subsets. See also Figure S4.
Article
ll
OPEN ACCESSDISCUSSION
The past decade has established ILCs as key players in orches-
trating tissue homeostasis and repair (Vivier et al., 2018). While
HIV infection is known to cause irreversible changes in some hu-
man tissues (Deeks et al., 2013), the impact on ILC number and
function remains incompletely understood, especially following
vertical HIV infection in blood and tissue during early life. We hy-
pothesized that innate lymphocyte responses may be particu-
larly important in pediatric HIV infection while the adaptive im-
mune response is still developing.
Here, we studied 229 individuals spanning the time from birth
to adulthood and show that circulating ILCs are dramatically
reduced in vertically HIV-infected individuals and are notCell Rrestored by successful long-term ART
unless it is initiated at birth. This is similar
to our finding in adult HIV infection, in
which only ART started in Fiebig stages
I–VI was able to preserve circulating
ILC levels (Kløverpris et al., 2016). How-
ever, unlike adult infection, in which tis-
sue-resident ILCs with tonsils were pre-
served, vertical HIV infection also
caused severe depletion of all ILC sub-
sets within these secondary lymphoid or-
gans. Remaining tissue-resident ILCs
displayed diverse responses to HIV
infection that involves proliferation, acti-
vation, and potential differentiation,
consistent with immune signatures
observed in lymph nodes from adultnon-human primates and human subjects (Mudd et al., 2018;
Wang et al., 2020). These data showing persistent transcrip-
tional activity suggest an ongoing functional role for lymph
node ILCs in pediatric HIV infection. The severe depletion of
these cells, therefore, seems likely to have long consequences
to the lymph node function and immune health.
Using a gating strategy previously shown to identify circulating
ILCs in adults (Kløverpris et al., 2016), we identify all known ILC
subsets within our pediatric subsets and confirmed four of these
subsets at the transcriptional level. Interestingly, we find that
helper ILC levels, but not cytotoxic NK levels, are highly elevated
in early life and decrease toward adolescence. This is consistent
with recent data from cord blood and peripheral blood of pediat-
rics in Caucasian populations (Ve´ly et al., 2016) and suggestseports 32, 108153, September 15, 2020 9
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response during early life while the adaptive immune response
is maturing.
The cohorts spanning early life to adolescence show in each
case that HIV infection reduces or depletes circulating helper
ILCs and CD56high NK cells in the absence of early ART interven-
tion. In our treatment-naive cohorts, we stratified for disease
control by comparing PSPs (Muenchhoff et al., 2016) and PPs
but found no overall differences in ILC subsets between these
otherwise clinically distinct groups. PSPs are characterized by
normal-to-age CD4 levels and very low immune activation
despite high viremia, in contrast to progressing children
(Muenchhoff et al., 2016). This does not agree with the findings
of Mudd et al. (2018), who found a direct correlation between
ILCs andCD4 levels in individuals. Importantly, however, that as-
sociation was observed in HIV-infected adults and in individuals
with non-HIV-associated reducedCD4 counts. This study shows
that ILC depletion in the context of vertical HIV infection, howev-
er, is clearly not directly related to CD4 counts. Indeed, our find-
ings may question the mechanistic relationship between CD4
count and circulating ILCs, as it is clearly not a dependent rela-
tionship. Moreover, virally suppressed pediatric individuals fol-
lowed longitudinally showed no reconstitution of helper ILCs or
CD56high NK cells despite normalization of CD4 levels. Consis-
tent with this, ILC levels in adolescents (14–18 years) remained
low despite >4 years of treatment. Alternative mechanisms sug-
gest HIV induced cytokines to drive ILC depletion (Wang et al.,
2020), although this was not investigated here.
While the importance of ILCs in tissue is now well established
(Vivier et al., 2018), ILCs’ function in blood remains unknown. Our
transcriptional profiling of blood ILCs showed robust transcrip-
tional responses for helper ILCs and NK cell subsets consisting
of DEGs associated with broad cellular activation. The fact that
IFN-g was predicted as an important upstream driver of this
response (except in ILC2s) is consistent with a pervasive role
for this cytokine in orchestrating peripheral immune responses
during chronic HIV infection (Roff et al., 2014). In adult HIV infec-
tion, apoptotic signatures were detected in acute HIV infection
and associated with ILC depletion (Kløverpris et al., 2016),
consistent with recent work in showing HIV-induced cytokines
can deplete ILC homeostasis in adult HIV infection (Wang
et al., 2020). However, no such apoptotic signature was de-
tected in the HIV-infected pediatric subjects studied here, who
were not in the acute phase. Indeed, upregulation of the antia-
poptotic factor BIRC3 in ILC2s and AXL and MET in ILCPs was
observed. We also observed significant upregulation of genes
enriched for metabolic pathways in ILC2s and ILCPs. Recent
work in healthy tissue has demonstrated that ILCs play an impor-
tant role in regulating dietary and tissue metabolism, and
changes in the cellular metabolism of ILCs can affect the immu-
noregulatory effects of these cells (O’Sullivan and Sun, 2017;
Wilhelm et al., 2017). Thus, although this study lacksmechanistic
detail, this gene modulation is consistent with published data
and may suggest a role for ILCs in the immunometabolic effects
of HIV infection. In the remaining ILCs sequenced from HIV-in-
fected tonsils, we did indeed detect an upregulation of genes
involved in metabolism. However, we do observe a clear signa-
ture of immune-related gene networks, including signaling and10 Cell Reports 32, 108153, September 15, 2020tissue repair. Surprisingly, we observed little impact from HIV
infection on CD4+ T cell subsets, including Tfh cells, in pediatric
tonsils. Direct matched comparison of CD4+ T cell subsets be-
tween blood and tonsils is needed to confirm this difference in
transcriptional response by compartment. Although further
work is needed, these data imply an ongoing role of ILCs within
secondary lymphoid organs of HIV-infected children. Whether
these are protective or detrimental to lymph node function in
these individuals remains to be seen.
In conclusion, we demonstrate the impact of lifelong HIV
infection on ILCs in both blood and lymphoid tissue. We used
well-defined cohorts differentiated by relative natural disease
control and time to treatment initiation at birth and early child-
hood. Despite their functional overlap to helper CD4+ T cells, it
is clear that ILCs in blood respond differently in both fre-
quencies and function to HIV infection and to antiretroviral
HIV treatment. Moreover, ILC responses at tissue effector sites
point toward a role for these cells as important regulators of tis-
sue homeostasis in chronic treated HIV infection. Properly
functioning lymph nodes are crucial for the generation of
optimal immune responses, and it is known that even treated
HIV-infected children have impaired immune responses to
both vaccination (Cagigi et al., 2012) and natural infection
(Muenchhoff et al., 2019). ILCs are required for the formation
of secondary lymphoid organs during development (van de Pa-
vert et al., 2014) and their proper functioning (Bar-Ephraı¨m and
Mebius, 2016). Thus, the depletion of ILCs observed in children
with lifelong HIV infection may contribute to suboptimal immu-
nity in these individuals. Crucially, the consequences of HIV
infection from birth in later life remain unknown. Understanding
the impact of HIV-induced depletion of ILCs in lymph nodes
may lead to interventions that improve immune function in
this vulnerable and important population.STAR+METHODS
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Antibodies
Anti-CD11c AF488 (Lineage) BioLegend 301618; RRID: AB_439791
Anti-CD14 FITC (Lineage) BD Bioscience 555397; RRID: AB_395798
Anti-CD19 FITC (Lineage) BD Bioscience 560994; RRID: AB_10563406
Anti-CD3 AF488 (Lineage) BioLegend 300320; RRID: AB_493691
Anti-CD4 FITC (Lineage) BioLegend 317420; RRID: AB_571939
Anti-TCRgd AF488 (Lineage) BioLegend 331208; RRID: AB_1575108
Anti-TCRab AF488 (Lineage) BioLegend 306712; RRID: AB_528967
Anti-CD34 FITC (Lineage) BioLegend 343604; RRID: AB_1732005
Anti-CD303 FITC (Lineage) BioLegend 354208; RRID: AB_2561364
Anti-CD19 FITC (Lineage) BD Bioscience 560994; RRID: AB_10563406
Anti-CD94 PerCp.Cy5.5 BD Bioscience 562361; RRID: AB_11152081
Anti-CD117 BV421 BioLegend 313216; RRID: AB_11148721
Anti-CD117 BV650 BioLegend 313221; RRID: AB_2562714
Anti-CD161 BV605 BioLegend 339915; RRID: AB_11142679
Anti-CD16 BV650 BioLegend 302042; RRID: AB_2563801
Anti-CD56 BV711 BioLegend 318336; RRID: AB_2562417
Anti-CD3 BV785 BioLegend 317330; RRID: AB_2563507
Anti-CD294 AF647 BD Bioscience 558042; RRID: AB_2112699
Anti-CD38 AF700 BioLegend 303516; RRID: AB_2072782
Anti-CD95 PE-CF594 BioLegend 305634; RRID: AB_2564221
Anti-CD127 Pe-Cy7 Beckman Coulter A14934; RRID: AB_2534372
Anti-CD4 BUV496 BD Bioscience 564651; RRID: AB_2744422
Anti-PD-1 BV421 BD Bioscience 562516; RRID: AB_11153482
Anti-CD103 BV605 BioLegend 350218; RRID: AB_2564283
Anti-CD69 BV785 BioLegend 310932; RRID: AB_2563696
Anti-CD3 PE-CF594 BD Bioscience 562280; RRID: AB_11153674
Anti-CD366 (NKp44) PE-Cy5 Beckman Coulter A66903; RRID: AB_2857937
Anti-CD8 BUV396 BD Bioscience 563795; RRID: AB_2722501
Anti-CD19 BUV496 BD Bioscience 564655; RRID: AB_2744311
Live/Dead Fixable Near-IR Dead Cell Stain Kit, 633nm Invitrogen L10119
Anti-IL-2 BV650 BD Bioscienceces 563467; RRID: AB_2738224
Anti-IL-4 FITC BioLegend 500807; RRID: AB_315126
Anti-IL-5 APC BioLegend 504305; RRID: AB_315329
Anti-IL-13 BV421 BioLegend 561158; RRID: AB_10561838
Anti-TNFa AFlour700 BD Bioscience 557996; RRID: AB_396978
Anti-IFNg PE-Cy7 BD Bioscience 557643; RRID: AB_396760
Anti-CD294 (CTRH2) PE-CF594 BD Bioscience 563501; RRID: AB_2738244
Anti-CD127 PE-Cy5 Beckman Coulter A64617; RRID: AB_2833010
Biological Samples
Human peripheral blood mononuclear cells (PBMCs) Human Cohorts
Human tonsil mononuclear cells (TMCs) Human Cohorts
(See Table 1)
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Chemicals, Peptides, and Recombinant Proteins
Maxima H-RT and Buffer ThermoFisher Scientific EP0751
dNTPs New England Biolabs N0447L
SUPERase*In RNase inhibitor ThermoFisher Scientific AM2696
Betaine solution, 5M, PCR Reagent Millipore Sigma B0300-5VL
KAPA 2x HiFi HotStart PCR mix Kapa Biosystems KK2602
RNAClean XP Beckman Coulter A63987
AMPure XP Beckman Coulter A63881
Nextera XT Kit Illumina, Inc FC-131-1096
Oligonucleotides
SMART Oligo dT IDT /5Biosg/AAGCAGTGGTATCAACGCAGAGTAC(T)30VN
Template-Switching Oligo IDT AAGCAGTGGTATCAACGCAGAGTACATrGrGrG
SMART PCR Primer IDT AAGCAGTGGTATCAACGCAGAGT
Software and Algorithms
FlowJo TreeStar v9.9.6
Prism GraphPad Software v8.4.3
DESeq2 Li and Dewey, 2011 V1.18.1
Ingenuity Pathway Analysis QIAGEN Inc. Winter 2019 Release
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Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact (henrik.
kloverpris@ahri.org).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The RNA-seq datasets supporting the current study have not been deposited in a public repository because the subjects from
which they were generated are at-risk children. The processed expression matrices are available upon request from the lead con-
tact. Access to the raw data will be considered on a case-by-case basis with supporting IRB approval on the behalf of the
requestor.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Peripheral blood (PB) samples from children were obtained from the Ithemabalabantu pediatric cohort in Durban, KwaZulu-Natal
(KZN), South Africa (Muenchhoff et al., 2016) and from Stanger Hospital, Stanger, KwaZulu-Natal (KZN), South Africa (Roider
et al., 2019). PB samples from newborn/infants were obtained from the Ucwaningo Lwabantwana (meaning learning from children)
infant cohort from Edendale, Mahatma Gandhi Memorial, Stanger and Queen Nandi Memorial Hospitals in KZN (Adland et al., 2020).
Tonsil tissue samples were obtained frompediatric patients undergoing routine tonsillectomy at Stanger Hospital, Stanger, KwaZulu-
Natal (KZN), South Africa (Roider et al., 2019). Informed consent was obtained from all adult study participants; and for underage
children and adolescents, informed consent was obtained from their guardians. All HIV infected individuals were infected via vertical
transmission from maternal HIV infection. For non-adult participants, 4 age groups were defined: 1. Newborns, aged 3–45 h; 2. In-
fants, aged 2–60 months; Paediatrics, aged 5–18 years. Paediatric slow progressors (PSP) were defined by stable CD4 T cell per-
centage of total PBMCs > 20% and found to be clinically healthy, while untreated pediatric progressors (PP) were defined by
CD4+ T cell percentage of total PBMCs < 20% or otherwise meeting requirements for treatment. The pediatric treated cohort
have individuals on antiretroviral therapy (ART). All subjects are from black Sub-Saharan ethnicity. This study was approved by
the respective institutional review boards and Biomedical Research Ethics Committee, University of KwaZulu-Natal (UKZN) in Dur-
ban, South Africa.Cell Reports 32, 108153, September 15, 2020 e2
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Cell isolation from human blood and tonsil
Peripheral blood mononuclear cells (PBMCs) were isolated by Histopaque 1077 (Sigma-Aldrich) density gradient centrifugation.
Tonsil tissue samples was minced and digested with Collagenase D (0.5 mg/ml; Roche) and DNase I (20 mg/ml; Sigma-Aldrich)
for 30 min in 37C shaking incubator. Digested tissue was passed through 70 mm cell strainers. Lymphocytes from the tonsil were
isolated by Histopaque 1077 (Sigma-Aldrich) density gradient centrifugation.
Flow cytometry analysis and cell sorting
For FACS analysis, different antibody panels for phenotype and intracellular cytokine staining (ICS) were used. A complete list of an-
tibodies used with identifier and source information can be found in the Key Resources Table. All samples were surface stained at
room temperature for minimum20min and near-infrared live/dead cell viability staining kit (Invitrogen). For experiments involving ICS,
the cells were stimulated with PMA (5 ng/ml; Sigma) plus Ionomycin (1 mg/ml; Sigma) in the presence of Golgiplug and Golgistop (BD
Biosciences) for 4 hr in 37C incubator. Cells were stained with fluorochrome-conjugated monoclonal antibodies and subsequently
fixed, permeabilized, and stained by BD Cytofix/Cytoperm Kit (BD Biosciences). Blocking with 20% goat serum for 20 min was done
prior to intracellular antibody staining. After staining cells were washed and fixed in 2% paraformaldehyde before acquisition on a 4
laser, 17 parameter BD FACSAria Fusion flow cytometer within 24 h of staining. Data were analyzed with FlowJo v.9.7.2 (TreeStar).
For cell sorting experiments, cells were processed from cryopreserved, surface stained, kept on ice in PBS and sorted immediately
after staining. All samples were surface stained at room temperature for a minimum 20 mins. Bulk populations were cell sorted to a
purity 99% on the BD FACSAria Fusion flow cytometer.
RNA isolation, library construction, sequencing, and alignment
CD4+ T cells, ILC2s, ILCPs, NK CD16high and NK CD56high cells from PBMCs and NKp44+ ILC3s, NKp44– ILC3s, NK CD127- and 4
distinct CD4+ T cell subsets from TMCs (100 cell replicates) were FACS sorted directly into 50 mL of RLT Lysis Buffer (QIAGEN)
supplemented with 1% v/v 2-mercaptoethanol. Briefly, 50 mL of mixed lysate from each sample was transferred to a skirted 96
well plate. Genetic material was pulled down and purified by mixing the lysate in each well with 2.2x volumes of Agencourt RNA-
Clean XP SPRI beads (Beckman Coulter) and washing 3x with 75 mL of 80% ethanol. After drying, the SPRI beads were re-sus-
pended in 4 mL of pre-reverse transcription (RT) mix, incubated for 3 min at 72C, and placed on ice. Next, Smart-Seq2 Whole
Transcriptome Amplification (WTA) was performed: 7 mL of RT mix was added to each well and RT was carried out; then,
14 mL of PCR mix was added to each well and PCR was performed. Thereafter a cDNA cleanup was performed using 0.6x
and 0.8x volumes of Agencourt AMPure XP SPRI beads (Beckman Coulter) which was then quantified using a Qubit dsDNA
HS Assay Kit (Life Technologies). Library size and quality were measured by Bioanalyzer using a High Sensitivity DNA Analysis
Kit (Agilent Technologies). Sequencing libraries were prepared from WTA product using Nextera XT (Illumina). After library con-
struction, a final AMPure XP SPRI clean-up (0.8 volumes) was conducted. Library concentration and size were measured with
the KAPA Library Quantification kit (KAPA Biosystems) and a TapeStation (Agilent Technologies), respectively. Finally, samples
were sequenced on a NextSeq500 (30 bp paired-end reads) to an average depth of 5 million reads. Reads were aligned to
hg38 (Gencode v21) using RSEM and TopHat (Li and Dewey, 2011) and estimated counts and transcripts per million (TPM)
matrices generated. Any samples with fewer than 5x105 or more than 6x106 aligned reads or fewer than 10,000 uniquely ex-
pressed genes were removed from subsequent analysis.
RNA-Seq Differential Expression Analysis
Differential expression analysis was performed using DESeq2 (v1.18.1) (Love et al., 2014). Expected counts from biological replicates
for each cell type and participant were averaged prior to differential expression in order to prevent participant specific genes from
generating false positives and reduce spurious heterogeneity from small (100-cell) populations. Small populationsmay show skewed
expression based on the cell composition within; thus this replicate averaging approach is particularly important given our limited
access to pediatric tissue sources and low frequency of these immune populations in order to remove further bias from small pop-
ulation sorts. See Tables S1 and S6 for replicate numbers. Tonsil analyses for the ILC3 and NK cell subsets were restricted only to
samples from female subjects given insufficient age matched male subjects. To calculate DEGs between cell subsets, we used the
design 1 + HIV.Status + Gender + Cell.Type in blood and the design 1 + HIV.Status + Cell.Type in tonsil. To calculate DEGs be-
tween HIV infected children and uninfected controls, we separated the samples by cell subset and used the designGender + HIV.-
Status for blood subsets and the design HIV for tonsil subsets. For the CD4+ T cell subsets in the tonsil, we used the design
Gender + HIV.Status as sample availability required us to use cells from both female and male participants.
Gene Set Analysis
Gene set analysis was performed using Ingenuity Pathway Analysis (IPA; Winter 2019 Release, QIAGEN Inc.) and Gene Set Enrich-
ment Analysis (GSEA) using the piano package in R (1.18.1). For IPA, DEGs whose FDR corrected q < 0.1 were used in the ‘‘Core’’
analysis with the log2FC and q values included in the analysis. To implement GSEA on our DESeq2 results, we used the log2FC of all
genes whose FDR corrected q < 0.1 as t-value input into the runGSA function with setting the argument geneSetStat = ‘‘gsea.’’ Wee3 Cell Reports 32, 108153, September 15, 2020
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OPEN ACCESSchose to use the KEGG and GO databases (downloaded from MSigDB v7.0) (Subramanian et al., 2005) for GSEA analysis as these
databases are well annotated for metabolic and cellular activation gene sets that are cell-type agnostic.
For the IPA enrichment on tonsil population comparisons, only 1-3 of the significantly enriched terms had non-N/A values for each
population. Thus, we have omitted the z-scores from the manuscript.
QUANTIFICATION AND STATISTICAL ANALYSIS
Graphs were plotted using Prism 8.4.3 (GraphPad Inc.) Differences between groups were analyzed using Mann Whitney U-test or
Dunn’s multiple comparisons test (two-sided) with specific test used stated in the figure legends otherwise. Data are presented
as the medians values with boxes representing IQR range and range by error bars, with a p value < 0.05 considered statistically sig-
nificant. The values of n refers to the number of participants used in study. In the other parts, it refers to the number of dependent
experiments.Cell Reports 32, 108153, September 15, 2020 e4
